Molecular status 36 months after TKI discontinuation in CML is
highly predictive for subsequent loss of MMR-final report from
AFTER-SKI

J 2021

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI

RICHTER, J., A. LUBKING, S. SODERLUND, K. LOTFI, B. MARKEVARN et. al.

Základní údaje

Originální název

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI

Autoři

RICHTER, J. (garant), A. LUBKING, S. SODERLUND, K. LOTFI, B. MARKEVARN, A. SJALANDER, L. STENKE, S. DENEBERG, E. AHLSTRAND, K. MYHR-ERIKSSON, P. PANAYIOTIDIS, T. GEDDE-DAHL, Daniela ŽÁČKOVÁ (203 Česká republika, domácí), Jiří MAYER (203 Česká republika, domácí), U. OLSSON-STROMBERG, F. X. MAHON, S. SAUSSELE, H. HJORTH-HANSEN a P. KOSKENVESA

Vydání

Leukemia, London, Nature Publishing Group, 2021, 0887-6924

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 12.883

Kód RIV

RIV/00216224:14110/21:00121497

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1038/s41375-021-01173-w

UT WoS

000618175800004

Klíčová slova anglicky

TKI discontinuation; CML; MMR-final report; AFTER-SKI

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 21. 10. 2021 10:00, Mgr. Tereza Miškechová

Anotace

V originále

Discontinuation of tyrosine kinase inhibitor (TKI) treatment for chronic phase (CP) CML patients with a deep molecular response (DMR) has entered standard practice. This is based on numerous clinical studies showing that ~50% of patients with DMR can stop TKI treatment without imminent disease relapse. However, in most of these trials long-term follow-up has been limited.

Citovat

RICHTER, J., A. LUBKING, S. SODERLUND, K. LOTFI, B. MARKEVARN, A. SJALANDER, L. STENKE, S. DENEBERG, E. AHLSTRAND, K. MYHR-ERIKSSON, P. PANAYIOTIDIS, T. GEDDE-DAHL, Daniela ŽÁČKOVÁ, Jiří MAYER, U. OLSSON-STROMBERG, F. X. MAHON, S. SAUSSELE, H. HJORTH-HANSEN a P. KOSKENVESA. Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI. Leukemia. London: Nature Publishing Group, 2021, roč. 35, č. 8, s. 2416-2418. ISSN 0887-6924. Dostupné z: https://dx.doi.org/10.1038/s41375-021-01173-w.

@article{1764396,
   author = {Richter, J. and Lubking, A. and Soderlund, S. and Lotfi, K. and Markevarn, B. and Sjalander, A. and Stenke, L. and Deneberg, S. and Ahlstrand, E. and MyhrandEriksson, K. and Panayiotidis, P. and GeddeandDahl, T. and Žáčková, Daniela and Mayer, Jiří and OlssonandStromberg, U. and Mahon, F. X. and Saussele, S. and HjorthandHansen, H. and Koskenvesa, P.},
   article_location = {London},
   article_number = {8},
   doi = {http://dx.doi.org/10.1038/s41375-021-01173-w},
   keywords = {TKI discontinuation; CML; MMR-final report; AFTER-SKI},
   language = {eng},
   issn = {0887-6924},
   journal = {Leukemia},
   title = {Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI},
   url = {https://www.nature.com/articles/s41375-021-01173-w.pdf},
   volume = {35},
   year = {2021}
}

TY  - JOUR
ID  - 1764396
AU  - Richter, J. - Lubking, A. - Soderlund, S. - Lotfi, K. - Markevarn, B. - Sjalander, A. - Stenke, L. - Deneberg, S. - Ahlstrand, E. - Myhr-Eriksson, K. - Panayiotidis, P. - Gedde-Dahl, T. - Žáčková, Daniela - Mayer, Jiří - Olsson-Stromberg, U. - Mahon, F. X. - Saussele, S. - Hjorth-Hansen, H. - Koskenvesa, P.
PY  - 2021
TI  - Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI
JF  - Leukemia
VL  - 35
IS  - 8
SP  - 2416-2418
EP  - 2416-2418
PB  - Nature Publishing Group
SN  - 08876924
KW  - TKI discontinuation
KW  - CML
KW  - MMR-final report
KW  - AFTER-SKI
UR  - https://www.nature.com/articles/s41375-021-01173-w.pdf
N2  - Discontinuation of tyrosine kinase inhibitor (TKI) treatment for chronic phase (CP) CML patients with a deep molecular response (DMR) has entered standard practice. This is based on numerous clinical studies showing that ~50% of patients with DMR can stop TKI treatment without imminent disease relapse. However, in most of these trials long-term follow-up has been limited.
ER  -

RICHTER, J., A. LUBKING, S. SODERLUND, K. LOTFI, B. MARKEVARN, A. SJALANDER, L. STENKE, S. DENEBERG, E. AHLSTRAND, K. MYHR-ERIKSSON, P. PANAYIOTIDIS, T. GEDDE-DAHL, Daniela ŽÁČKOVÁ, Jiří MAYER, U. OLSSON-STROMBERG, F. X. MAHON, S. SAUSSELE, H. HJORTH-HANSEN a P. KOSKENVESA. Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI. \textit{Leukemia}. London: Nature Publishing Group, 2021, roč.~35, č.~8, s.~2416-2418. ISSN~0887-6924. Dostupné z: https://dx.doi.org/10.1038/s41375-021-01173-w.

Podrobný výpis o publikaci